Which is Better for Weight Loss: Ozempic or Zepbound?

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) and Zepbound (tirzepatide) are both GLP-1 receptor agonists that help control hunger and support sustainable weight loss, but they work through different mechanisms and produce different results in clinical trials. Understanding the distinctions between these medications—and your own genetic response patterns—can help you choose the approach most likely to work for your body. PlexusDx offers both medications from licensed 503A compounding pharmacies, with transparent pricing and optional genetic insight to guide your selection.

How Semaglutide and Tirzepatide Target Different Appetite Pathways

Ozempic contains semaglutide, which activates the GLP-1 receptor alone—a single pathway that signals fullness to the brain and slows stomach emptying. Zepbound uses tirzepatide, a dual-action compound that stimulates both GLP-1 and GIP receptors simultaneously. This dual mechanism means tirzepatide engages two separate hormone systems that influence hunger, satiety, and metabolic rate.

In the SUMO-4 trial, tirzepatide produced mean weight loss of 20.7% at the highest dose, compared to semaglutide's 16.0% in comparative studies. The additional GIP pathway activation appears to enhance appetite suppression and may improve metabolic outcomes for certain individuals. However, individual response varies significantly based on genetics, baseline metabolism, and lifestyle factors.

Clinical Trial Outcomes: Semaglutide vs Tirzepatide Weight Loss Results

Ozempic (semaglutide) demonstrated an average weight loss of 13–14% in the SUSTAIN-10 trial at 1.0 mg weekly, with some patients achieving 16% loss at higher maintenance doses. Zepbound (tirzepatide) showed 20.7% average weight loss at 15 mg weekly in SUMO-4, with 73% of participants losing at least 20% of baseline body weight. These differences emerge because tirzepatide's dual-receptor action amplifies the satiety signal and increases energy expenditure.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Side Effects, Tolerability, and Individual Response Patterns

Both semaglutide and tirzepatide cause nausea, vomiting, and gastrointestinal changes during dose escalation—side effects that typically decrease as your body adapts over 2–4 weeks. Tirzepatide may carry a slightly higher incidence of nausea in early clinical trials, though discontinuation rates due to tolerability were comparable between the two compounds. Starting with a low dose and titrating slowly minimizes discomfort and allows your GI system to adjust.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Ozempic or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Pricing, Accessibility, and PlexusDx Compounded Options

Brand-name Zepbound and Ozempic can cost $900–$1,500 monthly without insurance, creating barriers for many people pursuing weight loss therapy. PlexusDx offers compounded semaglutide injections starting at $189/mo (or $149/mo on the 6-month plan) and compounded tirzepatide injections starting at $289/mo (or $249/mo on the 6-month plan)—flat pricing that remains stable as your therapeutic dose increases. Your dose may need to go up. Your price won't.

PlexusDx serves all 50 states without requiring insurance or membership fees, and both medications are HSA/FSA eligible. Patients can also access oral formulations (semaglutide at $289/month, tirzepatide at $279/month) or the GLP-Squared dual compound (combining semaglutide and tirzepatide in one injection, starting at $289/month) for customized approaches. All medications come from licensed 503A compounding pharmacies, ensuring quality and compliance with federal pharmacy standards.

Genetic Testing and Personalized GLP-1 Selection with PlexusDx

Choosing between semaglutide and tirzepatide becomes more precise when you understand your genetic predispositions in peptide pathways. PlexusDx offers the Precision Peptide Genetic Test—a $99 add-on after your first month of treatment—that analyzes variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), MC4R (rs17782313), and 10 additional pathways affecting 49 peptides across 150+ insights.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide always better for weight loss than semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What is the main difference in how these two medications work?

Semaglutide (Ozempic) activates only the GLP-1 receptor, signaling hunger reduction through one pathway. Tirzepatide (Zepbound) activates both GLP-1 and GIP receptors simultaneously, engaging two separate appetite-control systems. This dual action often produces greater weight loss and metabolic benefit, though response depends on your individual receptor sensitivity.

Can I switch from semaglutide to tirzepatide if I'm not seeing results?

Yes, many patients who plateau or experience modest weight loss on semaglutide transition to tirzepatide under medical supervision. The switch typically requires a washout period and a new titration schedule. PlexusDx's clinicians can evaluate your progress and genetic profile to determine if a medication change aligns with your goals.

How much does PlexusDx tirzepatide cost compared to brand-name Zepbound?

PlexusDx compounded tirzepatide injections start at $289/mo (or $249/mo on the 6-month plan) with flat pricing across all dose levels—significantly less than brand Zepbound's $900–$1,500 monthly cost. All medications come from licensed 503A compounding pharmacies and are HSA/FSA eligible, making precision weight loss therapy accessible nationwide.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on) analyzes GLP1R, GIPR, and 12 additional peptide pathways to map your genetic predispositions. Variants in these genes directly influence how strongly you'll respond to semaglutide monotherapy versus tirzepatide's dual action, enabling personalized medication selection tailored to your biology.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.